Literature DB >> 11074779

Access to palliative care and hospice in nursing homes.

J Zerzan1, S Stearns, L Hanson.   

Abstract

Nursing homes are the site of death for many elderly patients with incurable chronic illness, yet dying nursing home residents have limited access to palliative care and hospice. The probability that a nursing home will be the site of death increased from 18.7% in 1986 to 20.0% by 1993. Dying residents experience high rates of untreated pain and other symptoms. They and their family members are isolated from social and spiritual support. Hospice improves end-of-life care for dying nursing home residents by improving pain control, reducing hospitalization, and reducing use of tube feeding, but it is rarely used. For example, in 1997 only 13% of hospice enrollees were in nursing homes while 87% were in private homes, and 70% of nursing homes had no hospice patients. Hospice use varies by region, and rates of use are associated with nursing home administrators' attitudes toward hospice and contractual obligations. Current health policy discourages use of palliative care and hospice for dying nursing home residents. Quality standards and reimbursement rules provide incentives for restorative care and technologically intensive treatments rather than labor-intensive palliative care. Reimbursement incentives, contractual requirements, and concerns about health care fraud also limit its use. Changes in health policy, quality standards, and reimbursement incentives are essential to improve access to palliative care and hospice for dying nursing home residents. JAMA. 2000;284:2489-2494.

Entities:  

Keywords:  Death and Euthanasia; Health Care and Public Health; Professional Patient Relationship

Mesh:

Year:  2000        PMID: 11074779     DOI: 10.1001/jama.284.19.2489

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  26 in total

1.  Financing end-of-life care in the USA.

Authors:  C Raphael; J Ahrens; N Fowler
Journal:  J R Soc Med       Date:  2001-09       Impact factor: 5.344

2.  Advance care planning in nursing homes: correlates of capacity and possession of advance directives.

Authors:  Rebecca S Allen; Shermetra R DeLaine; William F Chaplin; Daniel C Marson; Michelle S Bourgeois; Katinka Dijkstra; Louis D Burgio
Journal:  Gerontologist       Date:  2003-06

3.  Rural-urban differences in end-of-life nursing home care: facility and environmental factors.

Authors:  Helena Temkin-Greener; Nan Tracy Zheng; Dana B Mukamel
Journal:  Gerontologist       Date:  2012-01-09

4.  The growth of hospice care in U.S. nursing homes.

Authors:  Susan C Miller; Julie Lima; Pedro L Gozalo; Vincent Mor
Journal:  J Am Geriatr Soc       Date:  2010-07-14       Impact factor: 5.562

5.  Racial disparities in in-hospital death and hospice use among nursing home residents at the end of life.

Authors:  Nan Tracy Zheng; Dana B Mukamel; Thomas Caprio; Shubing Cai; Helena Temkin-Greener
Journal:  Med Care       Date:  2011-11       Impact factor: 2.983

6.  Trends in the treatment of acute myeloid leukaemia in the elderly.

Authors:  Kathleen Lang; Craig C Earle; Talia Foster; Deirdre Dixon; Renilt Van Gool; Joseph Menzin
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

7.  Responding to ethical dilemmas in nursing homes: do we always need an "ethicist"?

Authors:  David A Fleming
Journal:  HEC Forum       Date:  2007-09

8.  Improving access to hospice care: informing the debate.

Authors:  Melissa D A Carlson; R Sean Morrison; Elizabeth H Bradley
Journal:  J Palliat Med       Date:  2008-04       Impact factor: 2.947

Review 9.  Barriers to excellent end-of-life care for patients with dementia.

Authors:  Greg A Sachs; Joseph W Shega; Deon Cox-Hayley
Journal:  J Gen Intern Med       Date:  2004-10       Impact factor: 5.128

10.  Treatment patterns, outcomes and costs among elderly patients with chronic myeloid leukaemia: a population-based analysis.

Authors:  Joseph Menzin; Kathleen Lang; Craig C Earle; Alastair Glendenning
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.